All studies
AuthorisedHuman Pharmacology (Phase I)- First administration to humansInterventional

A Phase I single-blind, randomised, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single and multiple rising doses of SIM0709 in healthy participants

This Phase I clinical trial is looking at a new potential treatment called SIM0709. In the future, doctors hope this medicine might help treat inflammatory bowel conditions, including Crohn’s disease and ulcerative colitis. However, before testing it in patients who are unwell, researchers must first make sure it is safe for humans. In this study, healthy adult volunteers will receive either the real medicine or a dummy treatment (placebo). Scientists will give participants gradually increasing doses to see how the body tolerates the drug and how it moves through the bloodstream. Because this is a 'first-in-human' study, participants are watched very closely by medical staff. The study does not offer personal medical benefits to the volunteers, but it provides crucial safety information needed to decide whether SIM0709 can move forward to help people living with Crohn’s disease and colitis.

At a glance

Status
Authorised
Phase
Human Pharmacology (Phase I)- First administration to humans
Sponsor
Simcere Pharmaceutical Co. Ltd.
Enrolment target
88
Start
04 Nov 2026

What is this study about?

Crohn’s disease and ulcerative colitis are long-term conditions where parts of the digestive system become inflamed and painful. For many people, existing treatments can stop working over time or cause unwanted side effects. Because of this, scientists are constantly searching for new, more effective therapies to help calm gut inflammation. SIM0709 is an experimental medicine developed with this goal in mind.

Before any new drug can be given to patients living with an illness, it must first go through Phase I clinical trials. This is the very first time the medicine is given to people. The main purpose of this study is not to cure an illness, but to answer basic safety questions: Does the body handle the medicine well? What side effects might occur? And how long does the drug stay in the blood? To answer these clearly without the confusion of existing bowel symptoms, researchers test the medicine in healthy volunteers first.

During the trial, participants receive either single or repeated doses that slowly increase in strength across different groups of volunteers. Medical teams will carefully check heart rate, blood pressure, blood samples, and general well-being. The findings from this trial will help doctors decide if SIM0709 is safe enough to be tested in future studies involving people who actually have Crohn’s disease or ulcerative colitis.

Key takeaways

  • This is a Phase I trial testing the safety of a new drug, SIM0709, in humans for the first time.
  • The drug is being developed to treat Crohn's disease and ulcerative colitis in the future.
  • The trial is recruiting healthy adult volunteers aged 18 and over, not people who currently have bowel disease.
  • Participants may need to stay in a specialised clinic for close monitoring and blood tests.
  • Taking part is voluntary, and participants are monitored closely by medical staff at all times.

Who may be eligible?

This study is looking for healthy adult volunteers aged 18 and older. Because this is an early safety trial, researchers need people who do not have major medical issues or active long-term illnesses.

To take part, you must be in generally good health. People who currently live with Crohn's disease, ulcerative colitis, or other chronic digestive disorders cannot take part in this specific early trial, as researchers need to see how the drug acts in a healthy gut first.

The research team will also check whether you take any regular prescription medications, have known drug allergies, or use nicotine or alcohol heavily, as these factors could interfere with how the trial medicine works.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am at least 18 years old.
  2. I consider myself to be in good general health.
  3. I do not have Crohn's disease, ulcerative colitis, or other serious bowel problems.
  4. I am comfortable staying in a clinic and having blood tests taken.
  5. I am willing to follow the study schedule and attend all required follow-up appointments.
Answer every question to see your result.

What does participation involve?

Taking part in this study typically involves an initial screening visit to check your overall health through blood tests, urine tests, and a heart check (ECG). If you are eligible, you will be assigned to receive either the study medicine (SIM0709) or a placebo, which looks identical but has no active ingredients. Neither you nor the study nurses will know which one you receive until the trial ends.

You may be asked to stay overnight at a dedicated clinical research unit for a few days so the medical team can monitor you closely, take regular blood samples, and check for any side effects. Some volunteers receive just a single dose, while others receive multiple doses over several days. After leaving the clinic, you will need to return for short follow-up visits so doctors can check on your recovery. The total duration of involvement usually ranges from a few weeks to a couple of months.

Potential risks and benefits

Because you must be healthy to join, taking part will not improve your own health. The main benefit is knowing you are helping scientists develop new treatments for people with painful bowel diseases. However, because this is the first time SIM0709 is given to humans, there are risks of unexpected side effects, which could range from mild symptoms like headache or nausea to more serious allergic reactions. You will be monitored around the clock by experienced doctors while dosing takes place. Taking part is completely voluntary, and you are free to leave the trial at any point without giving a reason.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

Why is a Crohn's medicine being tested on healthy people?

Testing new medicines in healthy volunteers first allows scientists to check their basic safety and how the body handles them without the confounding symptoms of an active illness.

What is a placebo?

A placebo is a harmless dummy treatment that looks and feels like the real medicine but contains no active drug. It helps researchers prove that any effects seen are truly caused by the study drug.

Will I be paid for taking part?

Phase I trials in healthy volunteers usually offer financial compensation to cover your time, inconvenience, and travel expenses. The trial team will explain this before you sign up.

What does 'single and multiple rising doses' mean?

It means the study starts with a very low dose in a small group. If it proves safe, the next group of volunteers receives a slightly higher dose, building up gradually under close supervision.

Can I leave the study early if I change my mind?

Yes. You have the legal right to withdraw from any clinical trial at any time, for any reason, without it affecting your future healthcare.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.